Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults

Published:2023-01-25 Issue:2 Volume:12 Page:663-675
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Chen Guiling,Li Nan,Dai Xiahong,Tu Shiyan,Shen Zhenwei,Wu Kaiqi,Jin Tinghan,Wu Jiajun,Peng Conggao,Sheng Guoping,Zhu Mengfei,Tang Lingling,Li Lanjuan

Funder

Staidson (Beijing) Biopharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-023-00759-4.pdf

Reference30 articles.

1. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region. Italy Jama. 2020;323(16):1574–81.

2. Jodele S, Köhl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol. 2021;178(14):2832–48.

3. Lipworth B, Chan R, Lipworth S, RuiWen KC. Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. J Allergy Clin Immunol Pract. 2020;8(6):1798–801.

4. Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22(2):77–84.

5. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design of antibody‐like peptides for targeting the human complement fragment protein C5a;Proteins: Structure, Function, and Bioinformatics;2023-11-07

2. The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics;International Immunopharmacology;2023-05